2018
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients. Journal Of The American Heart Association 2018, 7: e006940. PMID: 29301757, PMCID: PMC5778960, DOI: 10.1161/jaha.117.006940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCause of DeathDrug Therapy, CombinationFemaleHumansHydrochlorothiazideHypertensionMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSodium Chloride Symporter InhibitorsTime FactorsTreatment OutcomeConceptsHigh-risk hypertensive patientsCardiovascular risk reductionHypertensive patientsAntihypertensive regimenCombination therapyBlood pressure control statusGreater cardiovascular risk reductionRenin-angiotensin system blockadeAngiotensin-converting enzyme inhibitorPrimary composite eventsPrior antihypertensive therapyPrimary composite outcomeCalcium channel blockadeLipid-lowering medicationsPrior medication useCalcium channel blockersRisk reductionACCOMPLISH trialAntihypertensive therapySystem blockadeCardiovascular benefitsCombination regimenComposite outcomeDrug regimensMedication use
2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 2012, 381: 537-545. PMID: 23219284, DOI: 10.1016/s0140-6736(12)61343-9.Peer-Reviewed Original ResearchConceptsCardiovascular event ratesBody mass indexNormal weightPrimary endpointObese patientsEvent ratesCardiovascular outcomesCardiovascular protectionHypertension treatmentObese individualsHigher cardiovascular event ratesHigh-risk hypertensive patientsNon-fatal myocardial infarctionAmlodipine-based therapyAvoiding Cardiovascular EventsPatient’s cardiovascular outcomeSuperior cardiovascular protectionSystolic Hypertension (ACCOMPLISH) trialPrimary event rateSingle-pill combinationPrevious clinical trialsNormal weight categoryCardiovascular deathCardiovascular eventsHypertension trials
2011
Renal outcomes in hypertensive Black patients at high cardiovascular risk
Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney International 2011, 81: 568-576. PMID: 22189843, DOI: 10.1038/ki.2011.417.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBiomarkersBlack or African AmericanBlood PressureCalcium Channel BlockersCardiovascular DiseasesChi-Square DistributionCreatinineDiureticsDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionIncidenceKaplan-Meier EstimateKidneyKidney Failure, ChronicMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesUp-RegulationConceptsHigh cardiovascular riskNon-black patientsSerum creatinineCardiovascular riskEnd-stage renal diseaseBlood pressure goalsHypertensive black patientsAcute hemodynamic effectsEffective antihypertensive treatmentKidney disease progressionGlomerular filtration rateDouble-blinded mannerEvent-driven trialDisease end pointsACCOMPLISH trialAntihypertensive treatmentRenal outcomesEGFR lossHemodynamic effectsRenal diseaseBlack patientsBlack ethnicityFiltration rateDisease progressionPatientsPredictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Östergren J, Ibsen H, Weber M, INVESTIGATORS F. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Pressure 2011, 21: 82-87. PMID: 21830844, DOI: 10.3109/08037051.2011.598699.Peer-Reviewed Original ResearchConceptsSystolic blood pressureBetter SBP controlPrevious antihypertensive medicationsSBP controlAntihypertensive medicationsBaseline predictorsTreatment groupsHigher baseline systolic blood pressureCalcium channel blocker useUncontrolled systolic blood pressureHigher systolic blood pressureBaseline systolic blood pressureMain baseline predictorsUse of thiazidesSystolic BP levelsHigher diastolic BPMultivariable regression modelsLogistic regression modelsACCOMPLISH trialAmlodipine armRandomization armBlocker useCardiovascular outcomesInsulin useSystolic hypertension
2010
Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24-Hour Ambulatory Systolic Blood Pressure Control
Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA. Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24-Hour Ambulatory Systolic Blood Pressure Control. Hypertension 2010, 57: 174-179. PMID: 21189401, DOI: 10.1161/hypertensionaha.110.159939.Peer-Reviewed Original ResearchConceptsAmbulatory blood pressure monitoringBlood pressure controlSystolic blood pressureBlood pressure monitoringBlood pressureCardiovascular eventsTreatment armsCombination therapyPressure monitoringBlood pressure control ratesClinic systolic blood pressureNighttime systolic blood pressurePressure controlRenin-angiotensin system blockersSystolic blood pressure controlAdditional risk predictionAngiotensin system blockersAvoiding Cardiovascular EventsCombination of benazeprilSystolic Hypertension (ACCOMPLISH) trialBlood pressure effectsNighttime blood pressureEffects of drugsYear 2ACCOMPLISH trialCardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B, Investigators A. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal Of The American College Of Cardiology 2010, 56: 77-85. PMID: 20620720, DOI: 10.1016/j.jacc.2010.02.046.Peer-Reviewed Original ResearchConceptsRenin-angiotensin system blockersDiabetic patientsCardiovascular eventsSystem blockersHigh riskPrimary end pointAcute clinical eventsUnexpected adverse eventsPrimary eventACCOMPLISH trialCoronary benefitNondiabetic patientsCardiovascular deathCoronary revascularizationDiabetes groupAdverse eventsBlood pressureHypertension therapyClinical eventsCombination therapyMyocardial infarctionPatientsDiabetesHypertensionEnd pointRenal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, investigators F. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 2010, 375: 1173-1181. PMID: 20170948, DOI: 10.1016/s0140-6736(09)62100-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlbuminuriaAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCardiovascular DiseasesCreatinineDisease ProgressionDiureticsDouble-Blind MethodDrug CombinationsFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionKidney Failure, ChronicMaleMiddle AgedRisk FactorsConceptsChronic kidney diseaseKidney diseaseAmlodipine groupHydrochlorothiazide groupCardiovascular eventsCombination therapyHigh riskChronic kidney disease progressionEnd-stage renal diseaseFixed-dose combination therapyAvoiding Cardiovascular EventsBlood pressure goalsInitial antihypertensive therapyInitial antihypertensive treatmentPrespecified secondary analysisProgression of nephropathySystolic Hypertension (ACCOMPLISH) trialFrequent adverse eventsKidney disease progressionSerum creatinine concentrationTelephone-based interactive voice response systemAntihypertensive therapyAntihypertensive treatmentRenal outcomesCardiovascular morbidity
2008
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. New England Journal Of Medicine 2008, 359: 2417-2428. PMID: 19052124, DOI: 10.1056/nejmoa0806182.Peer-Reviewed Original ResearchConceptsNonfatal myocardial infarctionCardiovascular eventsNonfatal strokeCardiovascular causesMyocardial infarctionHigh riskEnd pointDihydropyridine calcium channel blockerCurrent U.S. guidelinesComposite of deathDouble-blind trialPrimary end pointPrimary outcome eventSecondary end pointsHigh-risk patientsAbsolute risk reductionRelative risk reductionCalcium channel blockersCombination drug therapySudden cardiac arrestRisk reductionCoronary revascularizationStudy drugAdverse eventsBaseline characteristicsPredictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Östergren J, Ibsen H, Weber M, Investigators F. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. Blood Pressure 2008, 17: 7-17. PMID: 18568687, DOI: 10.1080/08037050801972857.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAntihypertensive AgentsBenzazepinesBlood PressureDose-Response Relationship, DrugDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleFinlandHumansHydrochlorothiazideHypertensionMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsRacial GroupsRisk AssessmentScandinavian and Nordic CountriesTreatment OutcomeUnited StatesConceptsBlood pressureBP controlCombination therapyBaseline predictorsBP valuesCombination treatmentAbsolute BP valuesMain baseline predictorsPrevious antihypertensive medicationsLipid-lowering therapyUncontrolled blood pressureBlood pressure responseLarge outcome trialsLipid-lowering drugsSystolic BP valuesLogistic regression modelsBlinded baselineUncontrolled hypertensionAntihypertensive medicationsCardiovascular eventsSevere hypertensionSystolic hypertensionThiazide useOutcome trialsOverall patients
2007
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk
Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K, Investigators F. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. Blood Pressure 2007, 16: 13-19. PMID: 17453747, DOI: 10.1080/08037050701217643.Peer-Reviewed Original ResearchConceptsBody mass indexHigh cardiovascular riskCardiovascular eventsHypertensive patientsCardiovascular riskDiabetes mellitusCombination therapyNon-fatal cardiovascular endpointsCoronary artery bypass graftMean body mass indexAnti-lipid therapyAvoiding Cardiovascular EventsOral diabetes therapyPrevious antihypertensive treatmentSystolic Hypertension (ACCOMPLISH) trialDouble-blind treatmentAcute coronary syndromeArtery bypass graftAntihypertensive combination therapyHistory of strokePercutaneous coronary interventionAnti-platelet agentsACCOMPLISH trialAntihypertensive treatmentCardiovascular morbidityExceptional early blood pressure control rates: The ACCOMPLISH trial
Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M, Jamerson K, Bakris G, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen S, Cushman W, Papademetriou V, Weber M. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Pressure 2007, 16: 80-86. PMID: 17612905, DOI: 10.1080/08037050701395571.Peer-Reviewed Original ResearchMeSH KeywordsAmlodipineAntihypertensive AgentsBenzazepinesBlood PressureDouble-Blind MethodDrug Therapy, CombinationHumansHydrochlorothiazideHypertensionConceptsBP control ratesControl rateCombination therapyHigh-risk hypertensionMean BP changeMulti-national trialStage 2 hypertensionAnti-hypertensive medicationsBlood pressure controlACCOMPLISH trialMaximal medicationHypertension trialsMean BPRenal diseaseInitial treatmentBP changesHypotensive eventsCurrent guidelinesPressure controlHypertensionOverall trialPatientsTherapyTrialsAnalysis of variance